Cargando…
Phase I/II Study of Docetaxel and S-1 in Previously-Treated Patients with Advanced Non-Small Cell Lung Cancer: LOGIK0408
Background: As docetaxel plus S-1 may be feasible for cancer treatment, we conducted a phase I/II trial to determine the recommended docetaxel dose and the fixed S-1 dose (phase I), as well as confirm the regimen’s efficacy and safety (phase II) for previously-treated patients with advanced non-smal...
Autores principales: | Takayama, Koichi, Uchino, Junji, Fujita, Masaki, Tokunaga, Shoji, Imanaga, Tomotoshi, Morinaga, Ryotaro, Ebi, Noriyuki, Saeki, Sho, Matsukizono, Kazuya, Wataya, Hiroshi, Yamada, Tadaaki, Nakanishi, Yoichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947543/ https://www.ncbi.nlm.nih.gov/pubmed/31842381 http://dx.doi.org/10.3390/jcm8122196 |
Ejemplares similares
-
Randomized Phase II Study of First‐Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine in Elderly Patients with Untreated Non‐Small Cell Lung Cancer: LOGIK0801
por: Takayama, Koichi, et al.
Publicado: (2020) -
Prospective study of the UGT1A1*27 gene polymorphism during irinotecan therapy in patients with lung cancer: Results of Lung Oncology Group in Kyusyu (LOGIK1004B)
por: Fukuda, Minoru, et al.
Publicado: (2016) -
Digitale Logik
por: Stuckenberg, Hans Joachim
Publicado: (1970) -
Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1
*
28 or *
6 polymorphism: Results of the Lung Oncology Group in Kyushu (LOGIK1004A)
por: Fukuda, Minoru, et al.
Publicado: (2016) -
A single-arm, phase 2 study of adjuvant chemotherapy with oral tegafur-uracil for pathologically lymphovascular invasion positive stage IA non-small cell lung cancer: LOGIK0602 study
por: Tsuchiya, Tomoshi, et al.
Publicado: (2020)